Yaz Stroke, Heart Attack Settlement to Result in Payment of Another $56.9M

Bayer Healthcare has agreed to pay about $57 million to settle Yaz lawsuits and Yasmin lawsuits involving arterial thromboembolism (ATE) injuries, such as strokes and heart attacks, potentially resolving about 1,200 of the remaining cases over the controversial birth control pills.

The Yaz settlement agreement was announced in a court order (PDF) issued on Monday, outlining a voluntary program established for individuals pursuing claims over an arterial clot injury to resolve their case. However, at least 97.5% of those eligible must agree to participate or Bayer can withdraw from the settlement.

Bayer indicated last month that they continue to face about 4,000 product liability lawsuits over side effects of Yaz and Yasmin, after previously agreeing to pay about $2 billion to settle claims involving venous thromboembolism (VTE) injuries, such as deep vein thrombosis and pulmonary embolism. In an investor report issued for the second quarter of 2015, the drug maker estimated that about 1,200 of the remaining claims involved arterial clots.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

Following the announcement of the ATE resolution program, a settlement website (www.yazofficialatesettlement.com) was launched to provide details of the Master Settlement Agreement (PDF).

The agreement appears to have been reached last month, when several Yaz and Yasmin ATE lawsuits were slated to go to trial, but were postponed at the last minute.

On Monday, U.S. District Judge David R. Herndon, who is overseeing the federal Yaz and Yasmin litigation, placed a stay on all cases and called for a census of remaining claims to get an indication of how many cases will remain unresolved after the settlement program.

Since October 2009, the federal Yaz and Yasmin litigation has been consolidated for pretrial proceedings before Judge Herndon in the Southern District of Illinois.

At its peak, Judge Herndon presided over more than 12,000 complaints, which all involved similar allegations that Bayer failed to adequately warn women and the medical community about the potential side effects of Yaz and Yasmin, after the active ingredient drospirenone has been linked to an increased risk of blood clots, heart attacks, strokes and other injuries.


  • StephanieDecember 15, 2015 at 2:57 am

    Due to Yaz or Yasmine, my mother has had dvt. Several pulmonary embolism, Stroke and lives in nlood thinners. She also had a bleed out that. She is now in a wheel chair from the stroke and it seems that she will be on blood thinners indefinitely.

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted 2 days ago)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 4 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.